Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Pharmaceuticals & Biotechnology | Small Cap
Health Score : 5.31IOL Chemicals & Pharmaceuticals Ltd demonstrates a mixed financial performance. The company exhibits exceptional solvency, indicating a strong ability to meet its long-term obligations. Profitability is a notable strength, driven by healthy margins and returns on capital, equity, and assets. However, growth metrics present significant challenges, with declines in revenue, operating profit, EPS, and net income. Efficiency ratios also raise concerns, reflecting issues in asset utilization and working capital management. While liquidity is reasonable, it could be improved. The company's coverage ratios are strong, suggesting a good capacity to handle interest and dividend payments. Overall, IOL Chemicals & Pharmaceuticals showcases financial stability and profitability but needs to address its growth and efficiency to ensure sustained success. The healthcare industry's dynamics, including regulatory changes and market competition, could impact the company's future performance.
Health Score : 5.31IOL Chemicals & Pharmaceuticals Ltd demonstrates a mixed financial performance. The company exhibits exceptional solvency, indicating a strong ability to meet its long-term obligations. Profitability is a notable strength, driven by healthy margins and returns on capital, equity, and assets. However, growth metrics present significant challenges, with declines in revenue, operating profit, EPS, and net income. Efficiency ratios also raise concerns, reflecting issues in asset utilization and working capital management. While liquidity is reasonable, it could be improved. The company's coverage ratios are strong, suggesting a good capacity to handle interest and dividend payments. Overall, IOL Chemicals & Pharmaceuticals showcases financial stability and profitability but needs to address its growth and efficiency to ensure sustained success. The healthcare industry's dynamics, including regulatory changes and market competition, could impact the company's future performance.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
40.61
Industry Median
30.91
Small Cap Median
28.64
P/E RATIO
40.61
P/B RATIO
3.11
Industry Median
3.69
Small Cap Median
3.11
P/S RATIO
2.36
Industry Median
3.74
Small Cap Median
3.02
Others
PEG RATIO
-8.46
EV/EBITDA RATIO
18.92
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹190.48 as on Sep 1, 2026.
Growth Score : 2.80The growth ratios present a concerning picture of the company's recent performance. Revenue, operating profit, EPS, and net income have all experienced declines, indicating significant challenges in expanding the business. The asset growth rate is positive, suggesting some level of investment, but this is overshadowed by the negative trends in other key growth metrics. The company needs to address these issues to regain positive momentum.
Revenue Growth RatePoorOperating Profit Growth RatePoorEarnings Per Share (EPS) GrowthPoorAsset Growth RateExcellentNet Income Growth RatePoor| Growth Ratios | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Revenue Growth Rate | 1.51 | -3.79 | -2.53 | 11.54 |
| Operating Profit Growth Rate | -12.74 | 2.21 | -12.55 | 33.17 |
| Earnings Per Share (EPS) Growth | -16.99 | -3.38 | -24.89 | 36.34 |
| Asset Growth Rate | 3.06 | 10.98 | 6.15 | 8.61 |
| Net Income Growth Rate | -17.26 | -3.6 | -24.63 | 36.63 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
No Peer Data Is Available at This Moment.
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Analyzing moving average trends and crossovers. Green/Red badges indicate if the current condition passes or fails.
Comparing stock price performance (normalized) against benchmark indices over time.
Recent daily trading volume represented as a bar chart, alongside historical averages.
Current closing price relative to the 52-week highest and lowest prices.
No Stock Reports Available at This Moment.
IOL Chemicals & Pharmaceuticals Ltd. is a leading Indian manufacturer of Active Pharmaceutical Ingredients (APIs) and specialty chemicals. The company is one of the world's largest producers of Ibuprofen and also manufactures other key APIs, along with industrial chemicals like Ethyl Acetate, serving both domestic and international markets.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. IOL Chemicals & Pharmaceuticals Ltd's P/E ratio (TTM) is 40.61, compared to the industry median of 30.91 and large cap median of 28.64.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. IOL Chemicals & Pharmaceuticals Ltd's P/B ratio is 3.11, compared to the industry median of 3.69 and large cap median of 3.11.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. IOL Chemicals & Pharmaceuticals Ltd's P/S ratio is 2.36, compared to the industry median of 3.74 and large cap median of 3.02.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. IOL Chemicals & Pharmaceuticals Ltd's PEG ratio is -8.46.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. IOL Chemicals & Pharmaceuticals Ltd's EV/EBITDA ratio is 18.92.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. IOL Chemicals & Pharmaceuticals Ltd's ROE is 7.67%.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. IOL Chemicals & Pharmaceuticals Ltd's ROA is 10.40%.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. IOL Chemicals & Pharmaceuticals Ltd's ROCE is 11%.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. IOL Chemicals & Pharmaceuticals Ltd's operating margin is 11.60%.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. IOL Chemicals & Pharmaceuticals Ltd's net margin is 5.95%.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. IOL Chemicals & Pharmaceuticals Ltd's current ratio is 1.64.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. IOL Chemicals & Pharmaceuticals Ltd's debt-to-equity ratio is 0.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. IOL Chemicals & Pharmaceuticals Ltd's interest coverage ratio is 13.27.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. IOL Chemicals & Pharmaceuticals Ltd's DPS is ₹0.98.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. IOL Chemicals & Pharmaceuticals Ltd's EPS is 36.34.
(Source line: "Ratios as of 25 Sept 2026, based on last traded price of ₹190.48. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 1986
Headquarters: Shaheed Bhagat Singh Nagar, Punjab
Core Offerings: Ibuprofen, Metformin HCl, Lamotrigine, Gabapentin, Ethyl Acetate
Stock Listing: NSE (IOLCP), BSE (524164)
Promoter: Trident Group
IOL Chemicals & Pharmaceuticals Ltd. was incorporated in 1986. The company began commercial production of industrial chemicals, specifically Ethyl Acetate, in 1991. Over the years, it strategically diversified into Active Pharmaceutical Ingredients (APIs) manufacturing. A significant milestone was becoming one of the world's largest manufacturers of Ibuprofen. The company has since expanded its API portfolio and continuously invested in capacity expansion and backward integration to strengthen its market position in both pharmaceuticals and specialty chemicals.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| Pharmaceuticals (APIs) | 80-85% | Operating Profit |
| Specialty Chemicals | 15-20% | Operating Profit |
Pharmaceuticals (APIs): Focuses on manufacturing a diverse range of Active Pharmaceutical Ingredients for various therapeutic categories. Key products include Ibuprofen (where IOLCP is a global leader), Metformin HCl, Lamotrigine, and Gabapentin, catering to both regulated and semi-regulated markets.
Specialty Chemicals: Manufactures industrial chemicals, predominantly Ethyl Acetate. This product finds wide application in industries such as pharmaceuticals, printing inks, agrochemicals, and adhesives, leveraging captive raw material supplies for cost efficiency.
Mr. Varinder Gupta - Managing Director. He plays a pivotal role in the company's strategic direction and operational excellence. Mr. Vikas Gupta - Joint Managing Director & CEO, drives the company's growth initiatives and market expansion.
No major subsidiaries reported.
No major recent corporate actions on record.
The IOL Chemicals & Pharmaceuticals Ltd share price today is ₹190.48 on NSE (IOLCP), as of 26 Sept 2026.
As of 25 Sept 2026, IOL Chemicals & Pharmaceuticals Ltd share price is ₹190.48, with previous close ₹190.48. Today's range is ₹190.48 to ₹190.48. The 52-week range is ₹67.19 to ₹218.25.
As of today, IOL Chemicals & Pharmaceuticals Ltd's market cap is ₹5,472.49 crore (Mid Cap).
IOL Chemicals & Pharmaceuticals Ltd's current P/E ratio is 40.61, compared to the PHARMACEUTICALS & BIOTECHNOLOGY sector average of 37.10.
IOL Chemicals & Pharmaceuticals Ltd's current P/B ratio is 3.11.
IOL Chemicals & Pharmaceuticals Ltd's current dividend yield is 0.51%. Last dividend of ₹2.00 per share was declared on 27-May-2024.
IOL Chemicals & Pharmaceuticals Ltd's EPS (TTM) is ₹36.34.
IOL Chemicals & Pharmaceuticals Ltd. is a leading Indian manufacturer of Active Pharmaceutical Ingredients (APIs) and specialty chemicals. The company is one of the world's largest producers of Ibuprofen and also manufactures other key APIs, along with industrial chemicals like Ethyl Acetate, serving both domestic and international markets.
IOL Chemicals & Pharmaceuticals Ltd is promoted by Trident Group, holding 57.48% as of 25 Sept 2026.
IOL Chemicals & Pharmaceuticals Ltd is listed on NSE (IOLCP) and BSE (524164). Its next quarterly results are expected on Q2 FY25.
